Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Patients, aged 18 years or over, with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.~* Baseline testosterone \>1.5 ng/mL.~* Life expectancy of at least 12 months.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- degarelix 240/160 mg (Type: EXPERIMENTAL): Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.
- degarelix 240/80 mg (Type: EXPERIMENTAL): Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.
- Leuprolide 7.5 mg (Type: ACTIVE_COMPARATOR): Leuprolide (Lupron Depot) 7.5 mg IM (in the muscle) every 28 days starting at day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).